The private equity firm Blackstone Group is investing up to $2 billion in Alnylam Pharmaceuticals, a big bet on the Cambridge biotech’s approach to developing drugs for genetic diseases and disorders that need better treatments.
The deal, which was announced Monday, is anchored by Blackstone’s purchase of half the royalties owed to Alnylam on global sales of inclisiran, an experimental RNA interference drug for the treatment of high cholesterol.
